BeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival Benefit

BeiGene Ltd (NASDAQ:ONC) on Thursday announced the discontinuation of its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for lung cancer. The Independent Data Monitoring Committee recommended terminating the ongoing Phase 3 AdvanTIG-302…